A global biotech initiated a phase III study for severe allergic asthma. Study protocol originally accounted for enrolling 222 patients across nine UK-based investigator sites. The targeted recruitment rate for the first few months of the study was 14 patients per month, with full enrollment expected after 19 months of campaigning.
However, after deploying traditional recruitment methods, the sponsor only managed to randomize 20% of the target patient population in 11 months.
Trialbee partnered with the biotech during study start-up to get patient recruitment back on track and meet enrollment targets faster, which would not have been possible with a traditional recruitment approach.